TYSONS CORNER, Va., Oct. 28, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (OTCBB:SCRC) announced today that the Company's due diligence team will travel to China in November to begin formal RapiMed® distribution negotiations in preparation for a product launch into the Chinese OTC market, valued at over $32 billion.
ScripsAmerica plans to secure distribution commitments for its RapiMed® children's pain reliever and fever reducer during its upcoming five city trip across China. Representatives of the Company will conduct several meetings with hospitals, pharmacies, multi-level marketing companies and pharmaceutical sales networks.
"We are very excited to visit our partners in China who've already generated significant interest in RapiMed®. Because it's a truly unique product that addresses China's current problem with dangerous counterfeit medications flooding the market, we expect to generate several attractive distribution opportunities during our upcoming trip. ScripsAmerica believes RapiMed®'s ease of delivery and American-made quality assurance is the right product at the right time for the Chinese market. We are confident that our upcoming ventures in China will produce strong sales revenue for ScripsAmerica, greatly benefitting our shareholders," said CEO, Bob Schneiderman.
Schneiderman continued, "Our team will conduct pharmaceutical distribution meetings in the cities of Hong Kong, Chengdu, Yantai, Shenzhen and Beijing. Additionally, the Company has already begun to formally register RapiMed® with the Chinese State Food and Drug Administration which will allow ScripsAmerica to market and sell RapiMed® throughout the Chinese Market."
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and nutraceutical drugs, delivering pharmaceutical products to a wide range of end users across the health care industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information visit www.ScripsAmerica.com .
